01 9Effexor
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 336
2018 Revenue in Millions : 311
Growth (%) : 8
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 280
2021 Revenue in Millions : 317
Growth (%) : -12
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 263
2022 Revenue in Millions : 280
Growth (%) : -6
Main Therapeutic Indication : Neuroscience/Mental Health
Currency : USD
2014 Revenue in Millions : -21.80%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Neuroscience and Mental Health
Currency : USD
2015 Revenue in Millions : 344
2014 Revenue in Millions : 288
Growth (%) : -16%
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2016 Revenue in Millions : 278
2015 Revenue in Millions : 288
Growth (%) : -3
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2017 Revenue in Millions : 297
2016 Revenue in Millions : 277
Growth (%) : 7
Main Therapeutic Indication : Neurological/Mental Disorders
Currency : USD
2018 Revenue in Millions : 310
2017 Revenue in Millions : 297
Growth (%) : 4%
Upjohn (9 months)
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 242
2019 Revenue in Millions : 242
Growth (%) : 0
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
